SNGXHealthcare · BiotechnologySNGX Stock Forecast: Soligenix, Inc. Price Predictions for 2026-2027
The 1 Wall Street analysts covering Soligenix, Inc. hold a median 12-month price target of $1.75 — +363.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 23 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
SNGX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Soligenix, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (93): Smaller than most of the companies we track.
Issuance (9): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Soligenix, Inc. — and when they’d sell — is the membership.
SNGX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SNGX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +363.6% from it.
Of the 10 most recent actions, 1 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 July 2025 | Alliance Global Partners | Maintains | Buy | $10 → $6.00 |
| 4 Dec 2020 | B. Riley FBR | Initiates | Buy | — |
| 4 Dec 2020 | B. Riley Securities | Initiates | Buy | $4.00 |
| 28 July 2020 | Dawson James | Downgrade | Neutral | $3.00 → $2.00 |
| 31 Jan 2018 | H.C. Wainwright | Downgrade | Neutral | — |
| 31 Jan 2018 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 14 Aug 2017 | Maxim Group | Maintains | Buy | $4.00 → $5.00 |
| 17 July 2017 | H.C. Wainwright | Initiates | Buy | — |
| 17 July 2017 | HC Wainwright & Co. | Initiates | Buy | — |
| 7 Sept 2016 | Aegis Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SNGX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Soligenix, Inc. (SNGX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.2×
- Price / sales
- —
- Price / book
- 1.3×
- EV / EBITDA
- 0.0×
Cheaper than 77% of US stocks
Cheaper than 64% of US stocks
Cheaper than 61% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −326.9%
- Return on assets
- −99.7%
- Dividend yield
- —
Higher than 4% of US stocks
Higher than 3% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
SNGX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SNGX appears on the weeks it earns a place.
Frequently asked questions about SNGX stock
What is the SNGX stock price forecast for 2026-2027?
The 1 Wall Street analysts covering Soligenix, Inc. have a median 12-month price target of $1.75, with estimates ranging from $1.5 to $2. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is SNGX stock a buy right now?
Of the 1 analysts covering Soligenix, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Soligenix, Inc. 23 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank SNGX?
As at 1 Aug 2026, Soligenix, Inc. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).
Will SNGX stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies +363.6% from the last close, and Ticker Nerd's factor model ranks Soligenix, Inc. 23 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the SNGX stock forecast for 2030?
No analyst covering Soligenix, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SNGX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.5 to $2 over the next 12 months.
How has SNGX stock performed over the past year?
Soligenix, Inc. returned -86.2% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Soligenix, Inc. do?
Soligenix Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.
About Soligenix, Inc.
Soligenix Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. It operates through two primary segments: Specialized BioTherapeutics, which targets therapies for conditions like cutaneous T-cell lymphoma with products such as HyBryte, and Public Health Solutions, addressing vaccines and treatments for biological threats and infectious diseases. The company advances innovative biopharmaceuticals, including synthetic hypericin formulations, emphasizing rapid response and strong safety profiles in clinical studies. Soligenix Inc. plays a vital role in the biopharma sector by addressing niche markets for orphan drugs and emergency countermeasures, contributing to advancements in rare disease management and public health preparedness. Founded in 1987 and headquartered in Princeton, New Jersey, it continues to prioritize late-stage development in these specialized areas.
CEO Dr. Christopher J. Schaber Ph.D. · 13 employees · United States · https://www.soligenix.com